Trauma Under Psychedelics: How Psychoactive Substances Impact Trauma Processing
Ophir Netzer, Noa Magal, Yonatan Stern, Tzuk Polinsky, Raz Gross, Roee Admon, Roy Salomon
bioRxiv Preprint Server March 28, 2024 preprint DOI: 10.1101/2024.03.28.587237 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort |
|---|---|
| Sample size | 772 |
| Population | Adult survivors of the Supernova festival attack in Israel on October 7, 2023 |
| Duration | One to four months following the attack |
| Citations | 7 |
| Key findings | MDMA use during trauma exposure was associated with reduced psychological distress and better outcomes, while cannabis or alcohol use was associated with worse outcomes. |
Abstract
Traumatic events play a causal role in the etiology of stress-related psychopathologies such as depression and posttraumatic stress disorder (PTSD). Recent research highlighted the therapeutic potential of psychoactive substances in alleviating trauma symptoms among chronic stress-related patients. This study is the first to investigate the impact of psychoactive substances consumed during actual trauma exposure. Our cohort includes 772 adult survivors (487 males, Mean±SD Age: 26.96±6.55) of the high-casualty attack that occurred at the Supernova festival in Israel on October 7th, 2023. Survivors completed the study during the peritraumatic period of one to four months following the attack. Primary outcomes include the PTSD Checklist for DSM-5 (PCL-5), the Kessler Psychological Distress Scale (K6), and a self-reported rating of feeling overwhelmed. Secondary outcomes include subjective experiences during the attack and reports on social interactions and sleep quality. All survivors reported being in direct danger of death during the attack. Approximately two-thirds of the sampled survivors were under the influence of psychoactive substances at the time of the attack, including LSD, MDMA, Ketamine, Cannabis, and Alcohol, creating a tragic and unique natural experiment to study the impact of psychoactive compounds on trauma processing. Analysis revealed that participants that were under the influence of MDMA during the attack (n=99) reported feeling less overwhelmed, having more social interactions, improved sleep quality, and reduced psychological distress compared to those not under the influence of any substance during the attack (n=216). In contrast, those consuming Cannabis and/or Alcohol during the attack (n=68) showed higher psychological distress, more PTSD symptoms, and worse sleep quality compared to those not under the influence of any substance during the attack. Together, these novel findings suggest that trauma exposure under the influence of MDMA is associated with reduced psychological distress and higher sociality, possibly mediated through MDMA’s known effects of reducing negative emotions and elevating prosociality, while Cannabis and/or Alcohol consumption produces deleterious effects. Further research is needed to explore the cognitive and physiological mechanisms linking psychoactive substances to trauma recovery and establish the putative protective role of MDMA.
Citations in the library
Cited by 4
- How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder. Drugs November 1, 2024
- Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure. Journal of Psychopharmacology April 21, 2025
- Lifetime MDMA use and associations with meaning in life in the context of childhood trauma Scientific Reports February 10, 2026
- Societal Trends and Opportunities in the Aftermath of the Nova Psychedelic Trance Rave, Through Lilla and Benjamin Future Humanities February 25, 2025
Cites 16
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology September 1, 2019
- Reviewing the Potential of Psychedelics for the Treatment of PTSD The International Journal of Neuropsychopharmacology March 12, 2020
and 11 more in the library